Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer

References

• Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res.7, 2958–2970 (2001).
   PubMed Web of Science ®Google Scholar
• Herbst RS. Review of epidermal growth factor receptor biology. Int. J. Radiat. Oncol. Biol. Phys.59, 21–26 (2004).
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene19, 6550–6565 (2000).
   PubMed Web of Science ®Google Scholar
• Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J. Clin. Oncol.19, 32S–40S (2001).
   PubMed Web of Science ®Google Scholar
• Engebraaten O, Bjerkvig R, Pedersen PH et al. Effects of EGF, bFGF, NGF and PDGF(bb) on cell proliferative, migratory and invasive capacities of human brain-tumor biopsies in vitro. Int. J. Cancer53, 209–214 (1993).
   PubMed Web of Science ®Google Scholar
• Chan TO, Rittenhouse SE, Tsichlis PN. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Ann. Rev. Biochem.68, 965–1014 (1999).
   PubMed Web of Science ®Google Scholar
• Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J. Clin. Oncol.23, 2445–2459 (2005).
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Patel T, Dreisbach L et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter Phase III trial BMS099. J. Clin. Oncol.28(6), 911–917 (2010).
   PubMed Web of Science ®Google Scholar
• Ray M, Salgia R, Vokes EE. The role of EGFR inhibition in the treatment of non-small cell lung cancer. Oncologist14, 1116–1130 (2009).
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Yano S, Giaccone G et al. A multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (the IDEAL 1 trial). J. Clin. Oncol.21, 2237–2246 (2003).
   PubMed Web of Science ®Google Scholar
• Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA290, 2149–2158 (2003).
   PubMed Web of Science ®Google Scholar
• Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet366, 1527–1537 (2005).
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues PJ, Ciuleanu T et al. Erlotinib in previously treated non-small cell lung cancer. N. Engl. J. Med.353 (2005).
   Google Scholar
• Cappuzzo F, Ciuleanu T, Stelmakh L et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase 3 study. Lancet Oncol.11, 521–529 (2010).
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol.25(15), 1960–1966 (2007).
   PubMed Web of Science ®Google Scholar
• Reck M, Van Zandwijk N, Gridelli C et al. Erlotinib in advanced non-small-cell lung cancer (NSCLC): efficacy and safety findings of the global Phase IV trust study. J. Thorac. Oncol.5(10), 1616–1622 (2010).
   PubMed Web of Science ®Google Scholar
• Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N. Engl. J. Med.364, 947–955 (2011).
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Siu LL, Nemunaitis J et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol.19, 3267–3279 (2001).
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Horiike A, Fujisaka Y et al. Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50–8231 (erlotinib) in Japanese patients with solid tumors cancer. Chemother. Pharmacol.61, 489–496 (2008).
   PubMedGoogle Scholar
• Pérez-Soler R, Chachoua A, Hammond LA et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J. Clin. Oncol.22, 3238–3234 (2004).
   PubMed Web of Science ®Google Scholar
• Miller VA, Riely GJ, Zakowski MF et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J. Clin. Oncol.26(9), 1472–1478 (2008).
   PubMed Web of Science ®Google Scholar
• Jackman DM, Yeap BY, Lindeman NI et al. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J. Clin. Oncol.25(7), 760–766 (2007).
   PubMed Web of Science ®Google Scholar
• Kubota K, Nishiwaki Y, Tamura T et al. Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a Phase II study. J. Thorac. Oncol.3, 1439–1445 (2008).
   PubMed Web of Science ®Google Scholar
• Takahashi T, Yamamoto N, Nukiwa T et al. Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer. Anticancer Res.30, 557–564 (2010).
   PubMedGoogle Scholar
• Yoshioka H, Hotta K, Kiura K et al.; Okayama Lung Cancer Study Group. A Phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705. J. Thorac. Oncol.5, 99–104 (2010).
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Yu CJ et al. Randomized, placebo-controlled, Phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J. Clin. Oncol.27, 5080–5087 (2009).
   PubMed Web of Science ®Google Scholar
• Mok T, Park K, Au JS et al. Efficacy and safety of erlotinib in >1200 east/south-east asian patients with advanced non-small-cell lung cancer. J. Thorac. Oncol.5(10), 1609–1615 (2010).
   PubMed Web of Science ®Google Scholar
• Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Eng. J. Med.361, 958–967 (2009).
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu Y-l, Chen G et al. Preliminary results of randomized Phase III study comparing efficacy and safety of first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR-activating mutations (OPTIMAL). J. Clin. Oncol.28(Suppl. 15; Pt 1), 556s–7575s (2010).
   PubMedGoogle Scholar
• Hotta K, Kiura K, Takigawa N et al. Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience. J. Thorac. Oncol.5, 179–184 (2010).
   PubMed Web of Science ®Google Scholar
• Grunwald V, Hidalgo M. Development of the epidermal growth factor receptor inhibitor OSI-774. Semin. Oncol.30, 23–31 (2003).
   PubMed Web of Science ®Google Scholar
• Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small cell lung cancer: the Tarceva Lung Cancer Investigation trial. J. Clin. Oncol.25, 1545–1552 (2007).
   PubMed Web of Science ®Google Scholar
• Herbst RS, Prager D, Hermann R et al. TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer. J. Clin. Oncol.23, 5892–5899 (2005).
   PubMed Web of Science ®Google Scholar
• Yoneda KY, Shelton DK, Beckett LA, Gandara DR. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer. J. Thorac. Oncol.2(6), 537–543 (2007).
   PubMedGoogle Scholar
• Herbst RS, Johnson DH, Mininberg E et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J. Clin. Oncol.23(11), 2544–2555 (2005).
   PubMed Web of Science ®Google Scholar
• Miller VA, O’Connor P, Soh C et al. A randomized, double-blind, placebo-controlled, Phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J. Clin. Oncol.27(Suppl. 18; Pt 2), LBA8002 (2009).
   Web of Science ®Google Scholar
• Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist12, 610–621 (2007).
   PubMed Web of Science ®Google Scholar
• Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol.4, 107–119 (2009).
   PubMed Web of Science ®Google Scholar
• Lacouture ME, Maitland ML, Segaert S et al. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer18, 509–522 (2010).
   PubMed Web of Science ®Google Scholar
• Thatcher N, Nicolson M, Groves RW et al. UK erlotinib skin toxicity management consensus group. expert consensus on the management of erlotinib-associated cutaneous toxicity in the UK. Oncologist14(8), 840–847 (2009).
   PubMed Web of Science ®Google Scholar
• Tsimboukis S, Merikas I, Karapanagiotou EM, Saif MW, Syrigos KN. Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management. Clin. Lung Cancer10(2), 106–111 (2009).
   PubMedGoogle Scholar
• Gridelli C, Maione P, Amoroso D et al. Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an experts panel meeting. Crit. Rev. Oncol. Hematol.66, 155–162 (2008).
   PubMed Web of Science ®Google Scholar
• Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. FDA drug approval summary: erlotinib (Tarceva®) tablets. Oncologist10, 461–466 (2005).
   PubMed Web of Science ®Google Scholar
• Joensuu H, Trent JC, Reichardt P. Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat. Rev.37(1), 75–88 (2011).
   PubMed Web of Science ®Google Scholar
• Hopkins TG, Marples M, Stark D. Sunitinib in the management of gastrointestinal stromal tumours (GISTs). Eur. J. Surg. Oncol.34, 844–850. (2008).
   PubMed Web of Science ®Google Scholar
• Griffin JM, Amand MS, Demetri GD. Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors. Clin. J. Oncol. Nurs.9, 161–169 (2005).
   PubMedGoogle Scholar
• Demetri GD, Benjamin RS, Blanke CD et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST) – update of the NCCN clinical practice guidelines. J. Natl Compr. Canc. Netw.5(Suppl. 2), S1–S29 (2007).
   PubMedGoogle Scholar
• Deininger MW, O’Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J. Clin. Oncol.21, 1637–1647 (2003).
   PubMed Web of Science ®Google Scholar
• Pérez-Soler R, Delord JP, Halpern A et al. HER1/EGFR inhibitor-associated rash: Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist10, 345–356 (2005).
   PubMed Web of Science ®Google Scholar
• Scope A, Agero AL, Dusza SW et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J. Clin. Oncol.25, 5390–5396 (2007).
   PubMed Web of Science ®Google Scholar
• Hotta K, Kiura K, Tabata M et al. Interstitial lung disease in patients with non-small-cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group. Cancer J.11, 417–424 (2005).
   PubMed Web of Science ®Google Scholar
• Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science304, 1497–1500 (2004).
   PubMed Web of Science ®Google Scholar
• Hosokawa S, Toyooka S, Fujiwara Y. Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer. Lung Cancer66, 107–113 (2009).
   PubMed Web of Science ®Google Scholar
• Hotta K, Kiura K, Toyooka S et al. clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in japanese patients with non-small-cell lung cancer. J. Thorac. Oncol.2, 632–637 (2007).
   PubMed Web of Science ®Google Scholar
• Suehisa H, Toyooka S, Hotta K et al. Mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. J. Clin. Oncol.25, 3952–3957 (2007).
   PubMedGoogle Scholar
• Fujiwara Y, Kiura K, Toyooka S. Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer52, 99–103 (2006).
   PubMed Web of Science ®Google Scholar
• Fukui T, Otani S, Hataishi R et al. Successful rechallenge with erlotinib in a patient with EGFR mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease. Cancer Chemother. Pharmacol.65, 803–806 (2010).
   PubMedGoogle Scholar